{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '205270', 'Clinical Study Report(CSR)/equivalent summary unless local unless local', 'regulations or institutional policies require a longer retention period. No records', 'may be destroyed during the retention period without the written approval of the', 'sponsor. No records may be transferred to another location or party without', 'written notification to the sponsor', '12.2.7.', 'Source Documents', 'Source documents provide evidence for the existence of the participant and', 'substantiate the integrity of the data collected. Source documents are filed at the', \"investigator's site.\", 'Data reported on the CRF or entered in the eCRF that are transcribed from', 'source documents must be consistent with the source documents or the', 'discrepancies must be explained. The investigator may need to request previous', 'medical records or transfer records, depending on the study. Also, current', 'medical records must be available.', '12.2.8.', 'Study and Site Closure', 'GSK or its designee reserves the right to close the study site or terminate the study at any', 'time for any reason at the sole discretion of GSK. Study sites will be closed upon study', 'completion. A study site is considered closed when all required documents and study', 'supplies have been collected and a study-site closure visit has been performed. If GSK', 'determine such action is needed, GSK will discuss the reasons for taking such action with', 'the investigator or the head of the medical institution (where applicable). When feasible,', 'GSK will provide advance notification to the investigator or the head of the medical', 'institution, where applicable, of the impending action', 'The investigator may initiate study-site closure at any time, provided there is reasonable', 'cause and sufficient notice is given in advance of the intended termination.', 'Reasons for the early closure of a study site by the sponsor or investigator may include', 'but are not limited to:', 'Failure of the investigator to comply with the protocol, the requirements of the', \"IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines\", 'Inadequate recruitment of participants by the investigator', 'Discontinuation of further study treatment development', '12.2.9.', 'Records Retention', 'Following closure of the study, the investigator or the head of the medical', 'institution (where applicable) must maintain all site study records (except for', 'those required by local regulations to be maintained elsewhere), in a safe and', 'secure location.', 'The records must be maintained to allow easy and timely retrieval, when needed', '(e.g., for a GSK audit or regulatory inspection) and must be available for review', '80']['2016N298481_02', 'CONFIDENTIAL', '205270', 'in conjunction with assessment of the facility, supporting systems, and relevant', 'site staff.', 'Where permitted by local laws/regulations or institutional policy, some or all', 'of', 'these records can be maintained in a format other than hard copy (e.g.,', 'microfiche, scanned, electronic); however, caution needs to be exercised before', 'such action is taken.', 'The investigator must ensure that all reproductions are legible and are a true and', 'accurate copy of the original and meet accessibility and retrieval standards,', 'including re-generating a hard copy, if required. Furthermore, the investigator', 'must ensure there is an acceptable back-up of these reproductions and that an', 'acceptable quality control process exists for making these reproductions.', 'GSK will inform the investigator of the time period for retaining these records to', 'comply with all applicable regulatory requirements. The minimum retention', 'time will meet the strictest standard applicable to that site for the study, as', 'dictated by any institutional requirements or local laws or regulations, GSK', 'standards/procedures, and/or institutional requirements.', 'The investigator must notify GSK of any changes in the archival arrangements,', 'including, but not limited to, archival at an off-site facility or transfer of', 'ownership of the records in the event the investigator is no longer associated', 'with the site.', '12.2.10. Dissemination of Clinical Study Data', 'Study information from this protocol will be posted on publicly available clinical', 'trial registers before enrollment of subjects begins', 'Where required by applicable regulatory requirements, an investigator signatory', 'will be identified for the approval of the clinical study report. The investigator', 'will be provided reasonable access to statistical tables, figures, and relevant', 'reports and will have the opportunity to review the complete study results at a', 'GSK site or other mutually-agreeable location.', 'All study investigators will be provided with the full summary of the study', 'results. The investigator is encouraged to share the summary results with the', 'study subjects, as appropriate.', 'The procedures and timing for public disclosure of the results summary and for', 'development of a manuscript for publication will be in accordance with GSK', 'Policy.', '12.2.11.', 'Publication Policy', 'The results of this study may be published or presented at scientific meetings. If', 'this is foreseen, the investigator agrees to submit all manuscripts or abstracts to', 'the sponsor before submission. This allows the sponsor to protect proprietary', 'information and to provide comments.', 'The sponsor will comply with the requirements for publication of study results.', 'In accordance with standard editorial and ethical practice, the sponsor will', '81']\n\n###\n\n", "completion": "END"}